Published online before print December 16, 2002, doi: 10.1161/01.HYP.0000047668.48494.39
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:83.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Myocardial Fatty Acid Metabolism
Independent Predictor of Left Ventricular Mass in Hypertensive Heart Disease
From the Cardiovascular Imaging and Clinical Research Core Laboratory (L.d.l.F., L.R.P., V.G.D.-R.), the Center for Cardiovascular Research (D.P.K.), the Cardiovascular Division, Department of Medicine (L.d.l.F., L.R.P., D.P.K., R.J.G., V.G.D.-R.), and the Cardiovascular Imaging Laboratory, Mallinckrodt Institute of Radiology (P.H., R.J.G.), Washington University School of Medicine, St Louis, Mo.
Correspondence to Víctor G. Dávila-Román, MD, Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Box 8086, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110. E-mail vdavila{at}im.wustl.edu
The expression of myocardial fatty acid ß-oxidation enzymes is downregulated at the gene transcriptional level in animal models of left ventricular hypertrophy and of heart failure. Humans with idiopathic dilated cardiomyopathy have decreased myocardial fatty acid oxidation. The extent to which molecular mechanisms, such as a reduction in myocardial fatty acid oxidation, regulate the cardiac hypertrophic response in humans in vivo is unknown. Positron emission tomography was used to measure myocardial blood flow, oxygen consumption, fatty acid utilization, and oxidation in two groups of patients: (1) hypertensive left ventricular hypertrophy (n=19; left ventricular mass, 211±39 g; left ventricular ejection fraction, 67±4%) and (2) left ventricular dysfunction (n=9; left ventricular mass, 210±36 g; left ventricular ejection fraction, 31±10%); these were compared with a normal control group (n=36; left ventricular mass, 139±25 g; left ventricular ejection fraction, 66±6%). Left ventricular mass showed significant correlation with gender, diastolic and systolic blood pressure, myocardial fatty acid uptake, utilization and oxidation, myocardial blood flow, body mass index, and left ventricular ejection fraction (all P<0.02). Independent predictors of increased left ventricular mass were male gender (r=0.38, P<0.001), myocardial fatty acid oxidation (r=-0.24, P<0.018), systolic blood pressure (r=0.41, P<0.001), and left ventricular ejection fraction (r=-0.29, P=0.005). Thus, myocardial fatty acid metabolism is an independent predictor of left ventricular mass in hypertension and in left ventricular dysfunction. The extent to which reduced myocardial fatty acid metabolism affects cardiovascular morbidity and mortality and whether pharmacologic modulation results in improved outcomes remains to be determined.
Key Words: cardiac function • fatty acids • heart failure • hypertension, essential • hypertrophy • metabolism
This article has been cited by other articles:
 |
|
 |
|
  H. C. Champion, E. D. Michelakis, and P. M. Hassoun Comprehensive Invasive and Noninvasive Approach to the Right Ventricle-Pulmonary Circulation Unit: State of the Art and Clinical and Research Implications Circulation, September 15, 2009; 120(11): 992 - 1007. [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hammer, R. W. van der Meer, H. J. Lamb, H. H. de Boer, J. J. Bax, A. de Roos, J. A. Romijn, and J. W. A. Smit Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E714 - E718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Soto, P. Herrero, K. B. Schechtman, A. D. Waggoner, J. M. Baumstark, A. A. Ehsani, and R. J. Gropler Exercise training impacts the myocardial metabolism of older individuals in a gender-specific manner Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H842 - H850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Peterson, P. Herrero, J. McGill, K. B. Schechtman, Z. Kisrieva-Ware, D. Lesniak, and R. J. Gropler Fatty Acids and Insulin Modulate Myocardial Substrate Metabolism in Humans With Type 1 Diabetes Diabetes, January 1, 2008; 57(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Takahashi, T. Asai, H. Murakami, R. Murakami, M. Tsuzuki, Y. Numaguchi, H. Matsui, T. Murohara, and K. Okumura Pressure Overload-Induced Cardiomyopathy in Heterozygous Carrier Mice of Carnitine Transporter Gene Mutation Hypertension, September 1, 2007; 50(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. d. l. Fuentes, A. L. Brown, S. J. Mathews, A. D. Waggoner, P. F. Soto, R. J. Gropler, and V. G. Davila-Roman Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass Eur. Heart J., March 1, 2007; 28(5): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Goikoetxea, J. Beaumont, A. Gonzalez, B. Lopez, R. Querejeta, M. Larman, and J. Diez Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease Cardiovasc Res, March 1, 2006; 69(4): 899 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oikawa, Y. Kagaya, H. Otani, M. Sakuma, J. Demachi, J. Suzuki, T. Takahashi, J. Nawata, T. Ido, J. Watanabe, et al. Increased [18F]Fluorodeoxyglucose Accumulation in Right Ventricular Free Wall in Patients With Pulmonary Hypertension and the Effect of Epoprostenol J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1849 - 1855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Labarthe, M. Khairallah, B. Bouchard, W. C. Stanley, and C. Des Rosiers Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1425 - H1436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Skavdahl, C. Steenbergen, J. Clark, P. Myers, T. Demianenko, L. Mao, H. A. Rockman, K. S. Korach, and E. Murphy Estrogen receptor-{beta} mediates male-female differences in the development of pressure overload hypertrophy Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H469 - H476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Peterson, P. Herrero, K. B. Schechtman, S. B. Racette, A. D. Waggoner, Z. Kisrieva-Ware, C. Dence, S. Klein, J. Marsala, T. Meyer, et al. Effect of Obesity and Insulin Resistance on Myocardial Substrate Metabolism and Efficiency in Young Women Circulation, May 11, 2004; 109(18): 2191 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, P. J.H Smeets, A. J Gilde, and G. J van der Vusse Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res, February 1, 2004; 61(2): 218 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Czubryt and E. N. Olson Balancing Contractility and Energy Production: The Role of Myocyte Enhancer Factor 2 (MEF2) in Cardiac Hypertrophy Recent Prog. Horm. Res., January 1, 2004; 59(1): 105 - 124. [Abstract] [Full Text]
|
|
|
|
|
|
A. Gonzalez, M. A Fortuno, R. Querejeta, S. Ravassa, B. Lopez, N. Lopez, and J. Diez Cardiomyocyte apoptosis in hypertensive cardiomyopathy Cardiovasc Res, September 1, 2003; 59(3): 549 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Irie, I. B. Krukenkamp, J. F. F. Brinkmann, G. R. Gaudette, A. E. Saltman, W. Jou, J. F. C. Glatz, N. A. Abumrad, and A. Ibrahimi Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids PNAS, May 27, 2003; 100(11): 6819 - 6824. [Abstract] [Full Text] [PDF]
|
|